- Home
- PHUN vs RNXT Comparison
PHUN vs RNXT Comparison
Compare PHUN & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | RNXT |
|---|---|---|
| Founded | 2009 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 37.0M |
| IPO Year | 2016 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PHUN | RNXT |
|---|---|---|
| Price | $2.16 | $0.92 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $7.25 | ★ $8.25 |
| AVG Volume (30 Days) | 143.9K | ★ 281.7K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 39.36 | 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,883,000.00 | $1,123,000.00 |
| Revenue This Year | $89.86 | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.57 | ★ 2511.63 |
| 52 Week Low | $1.56 | $0.70 |
| 52 Week High | $3.88 | $1.45 |
Technical Indicators
Market Signals| Indicator | PHUN | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 49.85 |
| Support Level | $1.79 | $0.81 |
| Resistance Level | $2.30 | $1.07 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 32.61 | 53.97 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.